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Abstract 
  
The availability of quality pharmaceutical products impacts the lives of the global 
population on a daily basis. The importance of product availability and quality within 
pharmaceutical manufacturing requires that quality systems put into place are capable of 
accurately and robustly capturing the quality compliance, or lack thereof, of the various stages 
of production. This review intends to analyze current expert-recommended best practices 
within key elements of a pharmaceutical manufacturing quality control system and provide 
recommendations throughout. The quality elements discussed include Quality by Design 
method validation, necessary equipment determination, and equipment qualification, followed 
by documentation control and data flow.  
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PHARMACEUTICAL MANFUCTURING IN THE 21ST CENTURY:  
IDENTIFICATION AND ANALYSIS OF KEY ELEMENTS 
 
Introduction 
 For many decades, the pharmaceutical manufacturing industry was dominated by a 
regulatory framework that encouraged the assurance of quality by methods including batch-
based testing, raw materials testing, and end-product characterization (Vogt et. al., 2011). This 
“quality by quality control” approach yielded inefficiencies resulting from a lack of chemical 
engineering technology integration and manufacturing process flexibility. Due to rising drug 
development costs, increased global integration of pharmaceutical supply chains and mounting 
political pressure to increase access to affordable medications, pharmaceutical manufacturers 
have been pushed to find ways of cutting manufacturing costs while simultaneously continuing 
to improve the safety and quality of their drug products (Lawrence, 2008; Abboud, 2003). In the 
past, drug manufacturing processes have suffered from high, raw material waste and inefficient 
product generation due to a failure to gain full control of chemical manufacturing processes 
and hesitation to integrate new technologies (Rantanen et.al., 2015). Regulatory entities such 
as the U.S. Food and Drug Administration (US-FDA) and International Conference on 
Harmonization (ICH) have seemingly found a solution to this problem in the implementation of 
structured pharmaceutical development and manufacturing approaches (US-FDA, 2004; ICH, 
2005; ICH, 2006; ICH 2009; ICH, 2012). The emerging data-based frameworks Quality by Design 
(QbD) and Process Analytical Technology (PAT) seek to enhance the overall understanding of a 
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chemical manufacturing process by building quality directly into a processes design rather than 
testing for quality after the fact. This is achieved by performing development of a process with 
a complete understanding of the product and its manufacturing processes, while also ensuring 
a deep understanding of the risk involved in the processes and the requirements to mitigate 
these (Lawrence, 2008).  
 While gaining experience in multiple quality control laboratories for a leading 
pharmaceutical manufacturer, I became interested in answering the question of what 
operations were essential in establishing and maintaining a robust quality control program that 
reliably produced data that enhanced the control over the pharmaceutical manufacturing 
process.  In addition, I sought to investigate how might a quality program implement 
frameworks such as QbD to better understand its processes with the goal of cutting 
manufacturing costs and increasing product quality assurance. By combining my work 
experience within a quality control system with a review of available literature detailing the 
pharmaceutical manufacturing and quality control processes, I discovered three key aspects of 
pharmaceutical quality control that I found to be essential to the success of the quality control 
process. This review aims to bring readers up to date on current best practices of 
pharmaceutical manufacturing quality control by investigating Quality by Design method 
validation, instrumentation selection and qualification, and documentation control.  
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          Background Information 
I. Quality Method Validation 
Introduction 
 Much like the manufacturing process that involves a series of finely-tuned processes 
designed to result in the desired chemical product of interest, a quality control process must be 
designed in such a way that the data collected accurately reflects the quality and compliance of 
the pharmaceutical product (Nethercote, 2012). Whereas the manufacturing process’s product 
is the tablet, injection or ointment that is to be brought to market, a quality control process 
produces the data supporting the marketability of the product produced. Process validation is 
imperative to the accuracy of the data produced and is defined by the FDA in the January 2011 
Guidance for Industry titled, Process Validation: General Principles and Practices. The definition 
of process validation used by the FDA in this release is: “the collection and evaluation of data, 
from the process design stage through commercial production, which establishes scientific 
evidence that a process is capable of consistently delivering quality product.” (U.S. Food and 
Drug Administration, 2011). This FDA guidance links the process development phase and the 
product production phase to better reflect the importance of designing the validation process 
concurrently with production as compared to previous FDA advisories. Maintaining the scope of 
quality process validation, the “product” mentioned in the guidance would refer to the data 
produced by the process and its ability to accurately reflect the quality of the pharmaceutical 
product.  
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 The FDA guidance describes the recommended method for process validation in three 
distinct phases: 
Stage 1 – Process design: The quality testing workflow is designed during this stage on the basis 
of knowledge gained through development and scale-up activities. 
Stage 2 – Process qualification: The process design is evaluated to determine if the process is 
capable of reproducible data within acceptable limits under normal variation. 
Stage 3 – Continued process verification: Routine batch testing and data analysis provides 
assurance that the process is in a state of control. 
In addition to having a well-defined validation process as a manufacturer, it is imperative 
that during the validation process the following are well understood: 
• Sources of variation 
• Presence and degree of variation  
• Impact of variation on the process and product attributes 
• Methods to control variation in a manner commensurate with the risks it presents to 
the process and product  
This FDA guidance goes on to warn that focusing exclusively on qualification efforts without 
also understanding the manufacturing process and associated variations may not lead to 
adequate assurance of quality. To ensure maximum quality, manufacturers must maintain the 
process in a state of control over the life of the process, even as materials, equipment, 
production environment, personnel, and manufacturing procedures change (U.S. Food and 
Drug Administration, 2011). 
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 QbD (Quality by Design) principles of process validation, also used synonymously with 
the term “product life-cycle approach”, are described in ICH Q8, Q9, Q10 and Q11 guidance 
documents (ICH, 2005; ICH, 2006; ICH 2009; ICH, 2012). These principles should be 
implemented within every step of the quality process design process. The QbD/life-cycle 
framework enables increased process understanding and a more systematic and scientific 
approach to development, so that greater control can be established over the manufacturing 
and quality systems (Sandle et.al., 2012). Prior to integration of QbD/life-cycle principles, 
traditional process validation approaches rewarded a “check box” quality approach in which 
maintaining proper documentation of processes to uphold scrutiny by regulating body audits 
was valued greater than obtaining full understanding and control of the processes (Reid et.al., 
2013). 
 Integral to the implementation of a QbD process are the identification of analytical 
target profiles (ATPs) for products under control of the quality process. A product ATP outlines 
the specific measurements of a given quality attribute that are to be compared to the 
acceptance limits of the specification. The ATP also describes the maximum acceptable 
uncertainty in the reportable result and is the standard that must be achieved by the analytical 
procedure in question. The ATP acts as the focal point for the QbD process and allows for 
greater analytical control and risk assessment by helping integrate previously isolated validation 
activities (Nethercote, 2012).  
 
Process Validation Steps 
Step 1: Method Design  
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 The process development stage is one that should be continuous and, when properly 
done, should include a feedback loop in which the analytical methods, development and 
optimization evolve alongside any change to processes that could affect the method’s ability to 
produce data compliant with performance requirements (U.S. Food and Drug Administration, 
2011). After defining a product’s ATP, the most appropriate analytical technique should be 
determined. Each analytical technique at disposal should be evaluated in combination for its 
ability to produce ATP compliant data and align with practical business needs. Such business 
considerations include the technique’s use in development vs. in-process control (IPC), the 
practicality of use on/off-line, and cycle time considerations from sample gathering to data 
reporting (Rathore & Winkle, 2009). Each technique should be assessed, and a rationale 
documented, based on, primarily, the ability to generate consistent ATP data, and secondly, the 
unique business considerations of the process. An example of such analysis is depicted in Table 
1.1.  
 
 
Table 1.1: An example knowledge capture matrix focused on selecting a technique to measure a low 
concentration (5ppm) toxin in a final product. L, M and H represent “low” “medium” and “high” respectively.  
Information and table adapted from Ermer et.al., (2006) 
Separation 
Technique
Detection 
Technique
ATP (Accuracy 
and Precision 
Requirements)
Specificity Sensitivity 
Technology 
Available in 
manufacturing 
Environment? (Y, N)
Capability for 
at/on-line 
measurment? (Y, 
N)
Method 
Complexity 
(L, M, H)
Sample 
Preparation 
requirment 
(Y, N)
Cost Per 
Sample? 
(L, M, H)
Time from 
sample to 
reporting 
(L, M, H)
NP-HPLC DAD-UV ✓ ✓ ✗ Y Y L Y M M
DAD-UV-MS ✓ ✓ ✓ N N M Y H H
GC FID ✓ ✓ ✓ Y N L Y L M
MS ✓ ✓ ✓ N N M Y M H
CE DAD-UV ✓ ✓ ✗ Y N M Y L L
DAD-UV-MS ✓ ✓ ✗ N N H Y L M
SFC DAD-UV ✓ ✓ ✗ Y N L Y M M
DAD-UV-MS ✓ ✓ ✓ N N M Y M H
N/A NIR ✗ ✗ ✗ Y Y L N L L
Method Performance Requirement Businesss Critical Requirements
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Step 2: Method Development 
After successfully selecting an analytical method that fits within the capabilities of ATP 
requirements and practical business consideration, the sampling strategy should be developed, 
and a rationale documented (Ermer et. al., 2006). Sampling, again, will be dependent on the 
considerations of the specific product manufacturing process, as well as pertinent business 
concerns. The sampling process should be well developed as to accurately reflect the product 
being tested and minimize the variance to which the sampling process introduces (Nickerson, 
2011). Error prone sampling activities have the potential to detract from any control that QbD 
principles may add to a method.  
 Once a sampling procedure is established, the majority of method development involves 
fine-tuning ideal operating conditions of the analytical method specific to the sample and its 
components. Repeatability of this process and consistent production of data within an 
acceptable ATP range is necessary, therefore it is imperative to test the robustness of any 
procedure involved in sample preparation, instrumentation, and data analysis (Ermer et.al., 
2006). These activities are going to vary widely from product to product and the exact 
specification of the quality testing method should be developed on a case by case basis.  
 Background information about the product of interest should be thorough and 
extensive. Proper research and development activities prior to product scaling must result in 
the procurement of the necessary information regarding physiochemical properties, product 
strengths/weaknesses, formulation details, proprietary components and literature precedence 
(Sandle et.al., 2012). These product specific qualities should be used to guide decision making 
regarding the methodology design of the testing process. For example, the solubility of the 
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product will dictate which solvents are best to use in experiments requiring dilution. Knowledge 
of product chemical interactions with possible byproducts is essential to ensure that proper 
separation is achieved during pre-analysis separatory methods such as gas chromatography 
(GC) or liquid chromatography (LC) (Prager, 2019). Workflows are widely utilized in the 
pharmaceutical manufacturing sector to help guide decision making during the method design 
process and are recommended for use to assist in the organization of variables taken into 
account during the design process. An example of one such workflow is included in Figure 1.1., 
which includes the process by which a reverse-phase liquid chromatography (RP-LC) method is 
developed. This workflow includes stages of in silico and laboratory experiments followed the 
decisions made based on the data gained from such experiments in addition to prior 
knowledge.  
Method development is a multivariable activity and involves the integration of 
numerous sources of information in order to successfully develop a scientifically sound testing  
procedure that is capable of consistent production of statistically significant data regarding the 
quality of a pharmaceutical product (Rathore, 2009). Extensive case studies over various 
method developments completed by leading pharmaceutical manufacturers have been 
explored in literature and cases similar to those of interest should be referenced to ensure that 
the proper procedural steps scientific considerations are taken into account when developing a 
new quality testing method (El Deeb et.al., 2007; Bansal et.al., 2004; Bakeey, 2010). 
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Figure 1.1: Example workflow of an example RP-LC separatory method. Simliar work flows should be constructed to guide decision 
making activities.  Adapted from Ermer et.al., 2012 
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Step 3. Method Optimization 
 After properly designing a draft method to ensure that proper conditions are achieved 
and the process is capable of repeatedly producing significant data, the next step is to evaluate 
the method in further detail in order to enhance the stability and understanding of the process. 
Risk-assessments should begin at this point in the method design process and should involve 
use of the process in both the developmental (lab setting, non-production) and manufacturing 
settings as to increase the involvement of those individuals that will actually be using the 
method post-optimization (Sandle & Lamba, 2012). Risk assessment activities are intrinsic to 
the optimization process as they work to identify possible sources of error within the process as 
well as implement controls that work to remove such sources of error. This ensures that the 
data produced is ATP compliant. While undertaking risk assessment activities, the method must 
be separated into focus areas in which each area is individually evaluated for potential risk 
factors and possible controls (Sandle & Lamba, 2012). For example, when risk assessing a HPLC 
testing procedure, the sampling/sample preparation, run initiation, and data analysis activities 
should each be individually evaluated for potential pitfalls effecting data compliance. The 
variables effecting the method should then be evaluated for severity (with respect to potential 
effect on data), occurrence and detectability (Tang, 2011). Each variable should then be ranked 
(see cause and effect matrix) and categorized as controlled, background noise or experimental. 
Controlled variables are variables that can be controlled by setting parameter limits or adding 
specific instruction to the method (i.e. setting maximum age of active ingredient in mobile 
phase or strict ranges of buffer concentrations).  Noise is defined as a method variable that is 
difficult to control or predict (i.e. differences in stationary phase batches). Experimental 
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variables are variables that will affect ATP compliance of the data but can be easily understood 
and accounted for (Tang, 2011). Examples include temperature of solution and/or column and 
amount of sample diluted in a run solvent.   
 
II. Pharmaceutical Analysis Equipment 
Introduction 
Determining the right equipment and analysis methods to use when introducing a new 
quality control process to a production facility is key to ensuring the reliability of the data 
output by the method over the life-cycle of the manufacturing process. Identifying a 
production facilities equipment needs will vary widely from facility to facility, however the goal 
of the quality equipment involved in the process is essentially the same: to quantify or qualify 
key molecular ingredients throughout the manufacturing process of a pharmaceutical product 
(Bansal et.al., 2004). Achieving this analysis can be done in a multitude of methods which take 
advantage of the quantum and physiochemical properties of the molecules within an unknown 
compound or mixture. Techniques of pharmaceutical analysis include optical methods such as 
radiation absorption and radiation emission detection, chromatographic, electrochemical, 
radiochemical and thermal methods (Nethercote & Ermer, 2012). Each method will not be 
discussed at length in this section, but the technical backgrounds of the more prevalent 
techniques will be covered in brief. Further information regarding the technical aspects of 
various chemical analysis techniques can be found here (Bakeey, 2010; Bansal et.al., 2004; 
Ermer & Miller, 2006).  
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Following the determination of the necessary analytical techniques and equipment, all 
equipment used in the data collection process should be properly qualified to ensure reliability 
and control of the quality process. In August 2008, the United States Pharmacopeia (USP) 
General Chapter <1058> was published to advise on the analytical instrument qualification 
(AIQ) method. This guidance describes the AIQ framework and all necessary activities to ensure 
the fitness of analytical equipment within a pharmaceutical quality process (USP General 
Chapter <1058>, 2012). The AIQ is defined by the USP as “the collection of documented 
evidence that an instrument performs suitably for its intended purpose” (USP General Chapter 
<1058>, p.596, 2012). The qualification life-cycle is composed of four steps, commonly referred 
to as the “4Qs” of qualification: 
• DQ: Design qualification 
• IQ: Installation qualification 
• OQ: Operational qualification 
• PQ: Performance qualification 
The qualification life-cycle provides a foundation for the analytical process and successful 
testing and documentation of each step justifies subsequent quality activities such as method 
validation.  
 
Analytical Equipment Determination 
 The data produced by quality laboratories within pharmaceutical manufacturing 
facilities represent a key benchmark to ensuring the tablets and injections destined for the 
consumer market contain a chemical composition consistent with consumer and manufacturer 
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expectations. Ensuring that the proper chemical quality checks are completed prior to product 
release is dependent on the use of appropriate analytical techniques to produce data that 
provides information as to the various chemical qualities or quantities in a sample (Bedson & 
Sargent, 1996).  
 Pharmaceutical analytical techniques can be categorized as either qualitative or 
quantitative analysis. Qualitative analysis involves the non-quantitative identification of a 
constituent or substance within an unknown sample or compound. Identification refers to the 
confirmation of identity of the analyte(s) within a mixture. Quantitative analysis techniques are 
intended to determine the exact concentration of a specific analyte within a compound or 
mixture. Determination of an exact amount of active pharmaceutical ingredient (API) or 
unwanted reaction by-products is often the goal of quantitative analysis within pharmaceutical 
quality control programs. Quantitative analysis is often referred to as determination, while 
qualitative analysis is referred to as identification (Ermer & Miller, 2006). Common quantitative 
analysis methods within pharmaceutical manufacturing include titrimetric, gravimetric and 
volumetric analysis. Common qualitative analytical techniques include High-Performance Liquid 
Chromatography (HPLC), Mass Spectroscopy, and Inductively Coupled Plasma Mass 
Spectroscopy (ICP-MS). It should be noted however, that when coupled with proper 
experimental design and data analysis software many of the qualitative techniques mentioned 
can also be used to quantify analytes of interest.  
 Determining the necessary equipment when establishing a facility quality program will 
be highly dependent on a multitude of firm-specific variables and should be based on the 
intended purpose and scope of the analytical method. Process development activities (refer to 
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process validation section) will help guide the equipment determination process by providing 
the critical quality attributes (CQAs) of the product. Based on the CQAs, the quality laboratory 
staff can then decide which analytical method and equipment would best capture the variance 
of CQAs throughout the various stages of production. Parameters that should be taken into 
account when determining the appropriate method of analysis include specificity, range, 
linearity, limits of detection, limits of quantitation, accuracy and precision (Food and Drug 
Administration, 2015). Facilities quality staff will need to individually evaluate their available 
analytical methods for robustness of each of these parameters. This process should be based 
on mechanistic understanding of the methods and prior analytical experience. A systematic 
approach should be taken to determining the robustness of a method by conducting an initial 
risk assessment followed by multivariant experiments that follow the Design of Experiment 
(DOE) methods. This process will allow for a greater understanding of the effect of changes in 
the method parameters on the analytical procedure at large (Tang, 2011).  
 
Equipment Qualification 
Following the determination of the key analytical methods and their required 
equipment, each analytical device must be qualified as to ensure the reliability and compliance 
of the data that they are outputting. The AIQ framework outlined by USP General Chapter 
<1058>, is the industry standard for analytical instrument qualification. AIQ involves the steps 
of design, installation, operation and performance qualification to be completed and 
documented in order to justify the use of an analytical instrument to produce product quality 
data.  
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Design qualification (DQ) involves the documentation of the activities that define the 
functional and operational specifications of the instrument and the justification of the selection 
of the vendor based on the intended use of the instrument (USP General Chapter <1058>, 
2012). Often the manufacturer or designer of the instrument will complete the necessary DQ 
documentation as they are responsible for thorough documentation of design specification and 
functional requirements of the instrument. However, the user should confirm that the intended 
use of the instrument is suitable and that the manufacturer has adopted a quality system that 
ensures the reliability of the instrument.  
Installation qualification (IQ) requires the documentation detailing the activities 
necessary to establish that an instrument is delivered and designed as specified, properly 
installed in the selected environment, and that the environment in which the instrument is 
installed is suitable. The documented activities commonly involved in IQ include instrument 
description, instrument delivery consistent with purchase order, verification that the 
installation environment meets manufacturer specifications, assembly and installation 
performed correctly, potential networks or data storage are set up properly, and passing of all 
manufacturer diagnostics and tests (USP General Chapter <1058>, 2012). Equipment requiring 
installation qualification are those that are new or pre-owned, being moved to a new location 
or those that are being reinstalled.  
Operational qualification (OQ) is necessary to verify that the instrument is operational 
to its user requirement specifications within its installed environment. OQ involves the 
documentation of activities verifying the instruments operation specifications such as fixed 
operating parameters, confirmation of data storage, backup and archiving capabilities and 
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ensuring that parameters of operation meet user/manufacture specifications (USP General 
Chapter <1058>, 2012). 
 Performance qualification (PQ) is the collection of documented activities showing that 
the instrument consistently performs to user specifications and is suitable for the intended use. 
The activities documented commonly include tests/experiments producing data verifying the 
acceptable performance of the instrument for the intended purpose, preventative maintenance 
schedules and repairs and standard operating procedures (SOPs) for calibration, operation, 
maintenance and change controls (USP General Chapter <1058>, 2012).  
Operational qualification and performance qualification cannot be constituted by 
routine analytical testing. OQ and PQ testing must specifically address the verification of 
operation in accordance to specifications within the installed environment. Therefore, the 
repeated OQ/PQ testing may not be necessary and would only need to be completed if the 
instrument were to undergo a major repair or modification as to verify the continued operation 
is satisfactory. A chart outlining when qualification activities are necessary is included in Figure 
2.1. 
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Due to the high variance to which instruments of different use can affect the compliance 
of product data, USP<1058> utilizes a three-tiered, risk-based categorizing method to establish 
the extend of qualification activities that are necessary to demonstrate “fitness for purpose”. 
Group A includes standard equipment with no measurement capabilities or necessary 
calibration. The manufacturer’s specifications are accepted as user requirements and 
conformance can be verification/documented by visual observation. Group B instruments are 
those that control physical parameters (such as temperature, flow and pressure), produce 
relevant measurements and require calibration. User specifications are generally the same as 
manufacturer’s operational and functional specifications. Conformance of Group B instruments 
is determined according to the SOPs for the instrument or equipment and documented during 
Table 2.1: Timing and activities of equipment qualification activities throughout the qualification life-cycle. 
Information gathered from United States Pharmacopeia (2012). Table adapted from Ermer et. a.l, (2006) 
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IQ and OQ. Group B instruments include balances, ovens, water baths and refrigerator-freezers. 
Group C instruments include computerized analytical systems in which user requirements for 
functionality, operation and performance limits are specific to the analytical method. 
Conformance of Group C instruments is verified by specific performance and functionality tests. 
The full DQ, IQ, OQ, PQ qualification process should be completed for Group C instruments. 
Examples of these instruments include Mass spectrometers, Gas Chromatographs, UV/Vis 
spectrometers and HPLCs (USP General Chapter <1058>, 2012). 
 
III. Documentation of Pharmaceutical Quality Control Program 
Introduction 
 Effective management and control of documentation within the pharmaceutical 
industry is essential to cGMP compliance as it provides for full traceability of a product’s 
development, manufacturing and testing procedures (Patel & Chotai, 2011). Documentation 
provides the ability for regulatory bodies to assess the overall quality of a product as well as the 
operations and protocols within companies. Proper documentation programs within the 
pharmaceutical industry provide evidence of GMP compliance, ensuring that the end product 
destined for consumer use is void of harmful defects and compliant with quality expectations of 
regulating bodies. Proper documentation practices are a legal requirement for companies 
operating within the pharmaceutical sector, per FDA Code of Federal Regulations (CFR), 21CFR 
211.180(e), records and reports, which states: “written records…shall be maintained so that 
data therein can be used for evaluating… the quality standards of each drug product…”. Current 
GMP require that documents are: 
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• Controlled within the quality system 
• Approved, signed and dated 
• Regularly reviewed 
• Retained for a minimum time period 
• Able to be superseded within the quality system 
Within the quality control portion of the pharmaceutical manufacturing process, a proper 
documentation control program includes a documentation hierarchy composed of a mission 
statement, quality policies & quality manuals, policies, procedures & instructions, and records 
(Sandle, 2014).  The vast majority of documents within a pharmaceutical quality program will 
be procedures and records, with procedures generally consisting of SOPs. In addition to a 
documentation hierarchy, a proper documentation program will have a well-defined document 
handling system in place. Document handling encompasses a “creation-to-storage” outline for 
how documentation should be used to capture relevant data and guide the flow of information 
throughout an organization. Document handling can be described by the following three 
aspects:  
• Document Creation 
• Document Management  
• Document Control 
(Niazi, 2016) 
 
Drug manufacturers that have a well-defined and ubiquitous documentation handling system 
position themselves for long-term success within the bio-pharma sector through increased 
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information flow, continuous audit preparation, and improved control of the quality of product 
(Bargaje, 2011).  
 
Establishing A Document Handling System 
When considering the functionality of a quality control system within a pharmaceutical 
manufacturing environment, the system must be able to process the continuous input of 
quality data from multiple points in the manufacturing process in order to determine if product 
specifications are met. This requires that data is recorded accurately by machine technicians 
and processed by management thus to allow for timely decision making as to the quality, or 
lack thereof, of a production batch. In order for this system to allow for the efficient flow of 
data from sample testing to approval to product release, the documents themselves should be 
designed to present all of the necessary quality testing data in a clear and concise manner 
(Patel & Chotai, 2011). A standard documentation template should be drafted by the company 
following the classical documentation hierarchy. Shown in figure 3.1, the document hierarchy is 
designed to be a values-based guide to document creation that works to maintain that the 
values of the organization included in the mission statement trickle down throughout the 
organization during the creation of the company’s quality policy, corporate policies, procedures 
and records. This method works to ensure that all documented operating procedures are 
drafted based on the fundamental organization values.  
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 A robust documentation system is composed of three key components: creation, 
management and control (Sandle, 2014). Document creation can be thought of as its own 
process and is defined by the drafting and circulation of key documents by the steps of event 
capture, verification and approval, and communication. The event capture encompasses the 
detailing of the steps involved in the process. For example, when drafting a SOP for the process 
of analyzing a sample using HPLC, the detailed methods involved in sample preparation and use 
of the chromatograph would be included in the event capture phase. Following event capture, 
is the verification or approval stage of the document creation process. This involves a manager 
or authority on the subject matter to verify the accuracy of the document to ensure that the 
event captured is detailed correctly and that the data captured by the document is significant 
and useful to the quality process. Lastly, communication of the document must be completed 
so that all personnel affected by either the change of the policy/procedure or implementation 
herein, are aware and educated on the change within the process the document affects. 
Mission Statement
Quality Policy & 
Quality Manual
Policies
Procedures & 
Instructions
Records
Figure 3.1:  Graphical representation of a documentation hierarchy. Adapted 
from Sandle, (2014) 
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Training of pertinent staff as required would also be included within the communication step of 
document creation. Document management involves the activities surrounding the rules and 
mechanisms for creating and controlling documentation within a pharmaceutical 
manufacturing entity. Current CMP is very clear on what is expected from a document 
management program and leaves very little room for deviation as to ensure that companies 
operating in the pharmaceutical sector are essentially identical when it comes to document 
organization. A proper document management program involves layout, approval, 
authorization and unique identification of all documents is standardized by a master 
documentation SOP, as well as a master documentation SOP that includes: 
§ Procedures for issue, retrieval, re-issue, maintenance of currency and traceability 
§ Procedures for determining the need for documents 
§ Identification of documents to be included in batch dossiers (for batch release) 
§ Linkage of documents to licenses and regulatory requirements 
§ Outlining audit requirements for the documentation system 
§ Ensuring that only the most up to date version is ever used (superseding) 
§ Archiving and retention times 
(Niazi, 2016) 
Document control includes the retention of document standardization and the procedures that 
are in place to assure that documents are being used in the appropriate manner and that 
alterations to documents are not occurring without the proper approval process. Clarity, 
accuracy, currency, standardization of entries and traceability are all components of the 
documentation program that are maintained by document control (Bargaje, 2011). Control can 
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be achieved through a multitude of SOP implementation and training solutions which should be 
evaluated on a site by site basis.  
 A company should continually evolve good practices for document creation, 
management and control; timely identification of common errors allows for areas in which the 
program can improve. A capable documentation system within the quality control of 
pharmaceutical manufacturing is an essential to the success of the program due to the 
regulatory and highly technical environments of the field. A system that places an emphasis on 
proper documentation produces greater reliability of quality data and ensures the highest 
possible control over the capture and handling of data.  
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